15 results about "Dilated cardiomyopathy" patented technology

This application relates to the biomedical field and discloses a combination of biomarkers based on mitochondrial oxidative stress for the auxiliary diagnosis of dilated cardiomyopathy and its application. The biomarker combination includes the TARS2, NOX4, and SNCA genes. This biomarker combination can be used to prepare auxiliary diagnostic kits for dilated cardiomyopathy. By detecting the expression levels of each gene in the biomarker combination, the auxiliary diagnosis of dilated cardiomyopathy can be achieved efficiently and accurately. Compared with traditional diagnostic methods, this application, based on the characteristics of mitochondrial oxidative stress-related genes, has higher diagnostic accuracy and better applicability.

The application belongs to the field of genetic engineering, and particularly relates to a polynucleotide construct capable of expressing LMNA and application thereof in preventing and treating DCM. The synthetic intron in the application comprises: I) a nucleotide sequence as shown in SEQ ID No. 8, II) a nucleotide sequence having at least one mutation in the 1-8th position of the sequence shown in SEQ ID No. 8, or a nucleotide sequence having at least 90% homology with the sequence shown in I) or II). By using the synthetic intron in the application, two proteins can be simultaneously expressed through alternative splicing, and the ratio of the two proteins or the expression of a single protein can be regulated through mutation of the splicing signal. Compared with the existing gene therapy method for dilated cardiomyopathy caused by LMNA mutation, the expression vector for simultaneously expressing Lamin A and Lamin C proteins in the application has stronger rescue effect.

The application belongs to the technical field of molecular diagnosis, and particularly relates to extracellular vesicle lncRNA as a molecular marker for diagnosing heart failure combined with dilated cardiomyopathy. The molecular marker is NR_045681, and the specific nucleic acid sequence of the extracellular vesicle lncRNA is shown in SEQ ID NO. 5. The technical scheme provided by the application effectively improves the detection accuracy of heart failure combined with dilated cardiomyopathy. The P value of the combination of the molecular marker is less than 0.05, the |log fold change (FC)| is greater than 1, and the molecular marker has obvious differential expression relative to a healthy control group.

This invention discloses an intelligent terminal and early warning method for home management of dilated cardiomyopathy (DCM) in children, integrating multi-parameter monitoring, belonging to the field of intelligent health management technology. The method includes the following steps: establishing an electromagnetic event timeline in the home health monitoring environment; synchronously collecting and correlating electrocardiogram (ECG), blood oxygen saturation, and body movement signals according to a unified time reference to form an intelligent early warning baseline and generate a time anchor. This invention achieves synchronous correlation between multi-source physiological signals and interference by establishing an electromagnetic event timeline and time anchor, and dynamically rearranges sampling time to maintain signal continuity. Through a rhythmic breathing-type time control table and a dynamic interference isolation mechanism, the sampling rhythm is inversely coordinated with electromagnetic events, effectively improving the stability and accuracy of heart rhythm analysis and achieving intelligent early warning for dilated cardiomyopathy in children.

The application discloses application of SFRP3 in prevention and treatment of dilated cardiomyopathy, and belongs to the technical field of biological medicine. The application down-regulates SFRP3 expression in myocardial cells by means of gene interference, RNA interference technology, antibody or small molecule inhibitor, etc. to treat dilated cardiomyopathy, realizes the purposes of improving heart function, reducing cardiac dilatation, improving myocardial fibrosis and effectively promoting myocardial repair, and provides a more effective and low-side-effect treatment method for treatment of dilated cardiomyopathy. The treatment idea provided by the application can not only relieve symptoms of dilated cardiomyopathy, but also regulate physiological processes of heart cells at a molecular level, and provides a new idea for clinical treatment of dilated cardiomyopathy.

This invention discloses a targeted drug delivery system for treating dilated cardiomyopathy in children, relating to the field of targeted drug delivery technology. It includes a time baseline construction module, a heart rate mutation prediction module, a drug release rhythm control module, a phase-locked control module, and an energy distribution control module. The time baseline construction module establishes a unified time baseline during targeted drug delivery, integrating heart rate, blood flow velocity, and blood pressure signals in the same temporal order to generate a time reference baseline reflecting cardiac rhythm changes. This invention achieves time synchronization by establishing a unified time baseline and combining heart rate, blood flow, and blood pressure signals, ensuring that the drug release rhythm remains consistent with cardiac changes. Pre-emptive regulation is achieved through prediction windows and buffer indexes to eliminate feedback oscillations. The combination of a rhythm control table, phase-locked path, and energy distribution chain coordinates energy output with flow rate, maintaining stable and accurate drug delivery.

A maleate salt of the compound of Formula (I) is provided: Crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, atrial fibrillation, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; inflammatory or fibrotic diseases, cancer, epilepsy, Parkinson's disease, and Lafora disease.

This invention relates to the use of valproic acid in constructing animal models of dilated cardiomyopathy, and to a method for constructing such an animal model and screening drugs, belonging to the field of pharmaceutical technology. This invention involves administering 50-100 μM valproic acid to zebrafish farms. The dilated cardiomyopathy animal model constructed by this invention complements existing models. In drug screening applications, this complementarity effectively avoids the missed screening of candidate active compounds due to the limitations of a single model mechanism, significantly improving the comprehensiveness and success rate of screening. Simultaneously, the phenotype of the drug screening model of this invention is highly consistent with clinical findings, the model construction cycle is short and low-cost, and it can achieve dynamic visualization and be applied to high-throughput drug screening.

This invention discloses exosomal circRNA as a molecular marker for diagnosing dilated cardiomyopathy complicated with heart failure, relating to the field of molecular diagnostic technology. The exosomal circRNA is any one or a combination of two or more of the following molecular markers: hsa-circ-0026806, hsa-circ-0054400, hsa-circ-0074153, hsa-circ-0047519, hsa-circ-0063766, hsa-circ-0076771, hsa-circ-0019699, hsa-circ-0056066, and hsa-circ-0075837. The invention also discloses the application of exosomal circRNA as a molecular marker for diagnosing dilated cardiomyopathy complicated with heart failure. The exosomal circRNA is used as a marker for preparing kits, microarrays, or biochips for diagnosing dilated cardiomyopathy complicated with heart failure. The molecular marker provided by this invention effectively improves the detection accuracy of dilated cardiomyopathy complicated with heart failure. The combination of this molecular marker has a P value of <0.05 and |log fold change (FC)|>1, showing significant differential expression compared to the healthy control group.

This invention belongs to the field of biomedical technology and discloses a novel TNNT2 gene mutation c.311G>A associated with dilated cardiomyopathy. Through pedigree genetic analysis and in vitro functional validation, it was confirmed that this mutation leads to increased sensitivity of cardiomyocytes to doxorubicin and mitochondrial network fragmentation, thus exhibiting pathogenicity. Based on this, this invention provides specific detection primer pairs and kits for rapid genetic diagnosis and risk assessment of dilated cardiomyopathy.

This invention discloses an intelligent auxiliary diagnostic system for pediatric dilated cardiomyopathy (DCM) based on deep learning of cardiac ultrasound images, belonging to the field of intelligent auxiliary diagnostic technology. It includes a multi-source synchronous acquisition module, a passive displacement recognition module, a time-series baseline rearrangement module, an apical stabilization window module, and a risk assessment output module. The multi-source synchronous acquisition module acquires continuous cardiac ultrasound image sequences, probe contact pressure information, and chest wall displacement signals, writing these data sequentially into the same time series chain to establish a traceable time anchor for subsequent dynamic analysis. This invention ensures temporal consistency of cardiac ultrasound data through multi-source synchronous acquisition and time anchor alignment. Combined with passive displacement feature bands and an apical stabilization window, it enables the identification and removal of abnormal segments, effectively suppressing non-physiological deformation interference and improving the stability of cardiac dynamics analysis and the accuracy of dilated cardiomyopathy diagnosis in children.

The present invention provides a process for preparing substituted pyrazole compounds of Formula II, which are useful as intermediates for preparing substituted piperidine urea compounds useful for treating dilated cardiomyopathy (DCM).R 2 is independently selected from F, C1-C4 alkyl, C1-C4 haloalkyl,R 3 is independently selected from H, F, C1-C4 alkyl, C1-C4 haloalkyl,R 4 is C1-C4 alkyl,R 6 is H or a protecting group, andR 7 is selected from H, CI or trialkylsilyl.

This application provides LMNA Mutated genes and their applications belong to the field of biomedical technology. Humans LMNA The nucleotide sequence of the mutated gene is shown in SEQ ID NO.1. LMNA Mutant genes can be used for screening dilated cardiomyopathy and atrioventricular block, and for constructing non-human animal models of dilated cardiomyopathy and atrioventricular block. This is beneficial for exploring the pathophysiological processes of dilated cardiomyopathy and atrioventricular block, as well as for discovering therapeutic targets and drugs for dilated cardiomyopathy and atrioventricular block.

The present invention provides a method for treating diseases or conditions that respond to HDAC6 inhibition, such as metabolic diseases and conditions, heart failure with preserved ejection fraction (HFpEF), and dilated cardiomyopathy, said method being performed by orally administering to a subject a daily dose of about 10 mg to about 300 mg of a compound 1 having the following formula: (1), or a pharmaceutically acceptable salt thereof.